Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB | BSE: 539524

Falling Comet

Download real time

1325.40 -21.20 (-1.57%)

25.12% Fall from 52W High

271.4K NSE+BSE Volume

NSE 27 Mar, 2026 3:31 PM (IST)

22,207.7

Market Cap

Market Runner Up

-

Beta 1Year

Very Low volatility

Dr. Lal Pathlabs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LALPATHLAB, BSE:539524 Dr. Lal Pathlabs Ltd.

Search Inside the pdf :

Dr. Lal Pathlabs Ltd.

17 Feb 2026

1325.40

-1.57%

DR. LAL PATHLABS LIMITED

buy

Hold: Dr. Lal Pathlabs Ltd.

Geojit BNP Paribas

EBITDA rose 16.4% YoY to Rs. 179cr, and the margin expanded 140 basis points (bps) YoY to 27.2%, driven by sustained volume growth, network expansion and a favourable mix, combined with the efficient hub-and-spoke model and technology...

Dr. Lal Pathlabs Ltd. is trading below all available SMAs

Dr. Lal Pathlabs Ltd.

02 Sep 2025

1325.40

-1.57%

DR. LAL PATHLABS LIMITED

buy

Hold: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

*over or under performance to benchmark index Dr Lal PathLabs Ltd (DLPL) provides diagnostic tests and services globally. As of December 2024, DLPL had 280 clinical laboratories, including a national reference lab...

Number of FII/FPI investors decreased from 391 to 378 in Dec 2025 qtr

Dr. Lal Pathlabs Ltd.

20 Jul 2025

1325.40

-1.57%

FY25 AR: Stable outlook despite leadership transition

buy

Buy: Dr. Lal Pathlabs Ltd.

Emkay

Following the slump in FY23, DLPL has registered revenue/EBITDA/PAT CAGR of 10%/19%/43%, respectively, over the last two years.

Dr. Lal Pathlabs Ltd. is trading below all available SMAs

Dr. Lal Pathlabs Ltd.

12 May 2025

1325.40

-1.57%

DR. LAL PATH LABS LTD.

buy

Buy: Dr. Lal Pathlabs Ltd.

FundsIndia

Number of FII/FPI investors decreased from 391 to 378 in Dec 2025 qtr

Dr. Lal Pathlabs Ltd.

26 Apr 2025

1325.40

-1.57%

Decent quarter, limited headroom for margins expansion

buy

Hold: Dr. Lal Pathlabs Ltd.

Target

ICICI Securities Limited

Dr Lal PathLabs’ (Dr Lal) Q4FY25 results were slightly better than our expectation. Outperformance was driven by higher sample volumes (up 9.5% YoY) and realisation improvement.

Dr. Lal Pathlabs Ltd. is trading below all available SMAs

Dr. Lal Pathlabs Ltd.

26 Apr 2025

1325.40

-1.57%

Steady quarter; encouraging outlook

buy

Buy: Dr. Lal Pathlabs Ltd.

Target

Emkay

DLPL reported a steady Q4, with EBITDA beating street/our estimates by 6% and adj PAT improving 34% on YoY basis. Strong performance in core markets (Delhi NCR), buoyed by network expansion, offset the persistent muted performance of Suburban (mid-single digit revenue growth).

Dr. Lal Pathlabs Ltd. has an average target of 1577.00 from 4 brokers.

Dr. Lal Pathlabs Ltd.

14 Feb 2025

1325.40

-1.57%

DR. LAL PATHLABS LIMITED

buy

Accumulate: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

Dr. Lal Pathlabs Ltd. is trading below all available SMAs

Dr. Lal Pathlabs Ltd.

13 Jan 2025

1325.40

-1.57%

DR. LAL PATHLABS LTD.

buy

Sell: Dr. Lal Pathlabs Ltd.

Ventura

Elevated Valuations Dampen Strong Fundamentals

Number of FII/FPI investors decreased from 391 to 378 in Dec 2025 qtr

Dr. Lal Pathlabs Ltd.

24 Oct 2024

1325.40

-1.57%

Growth moderates; near term green shoots unlikely

buy

Hold: Dr. Lal Pathlabs Ltd.

Target

ICICI Securities Limited

Dr Lal PathLabs’ (Dr Lal) Q2FY25 revenue growth of 9.8% YoY was lower than our expectation, though its better EBITDA margin of 30.7% was a surprise.

Number of FII/FPI investors decreased from 391 to 378 in Dec 2025 qtr

Dr. Lal Pathlabs Ltd.

22 Aug 2024

1325.40

-1.57%

DR. LAL PATHLABS LIMITED

buy

Hold: Dr. Lal Pathlabs Ltd.

Recommendation Target

Geojit BNP Paribas

Dr. Lal Pathlabs Ltd. has an average target of 1577.00 from 4 brokers.

Is Dr. Lal Pathlabs Ltd. worth buying?

233 Votes:

Buy 76.39%

Sell 14.59%

Hold 9.01%

RESEARCH REPORTS

Hold SEE REPORTS >

Hold SEE REPORTS >